ArticleJournal of translational internal medicine2025
Lnc5q21.2, a novel long intergenic RNA, sensitizes colorectal cancer cells to ATR inhibitor by activating Wnt pathway.
Article in Journal of translational internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epigenetic silencingCancer biology & therapy · 2026Article
- The effect and mechanism of TIPE in promoting M2 polarization through DcR3 in the microenvironment of colorectal cancer.Cancer immunology, immunotherapy : CII · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Colorectal cancer (CRC) is still the leading cause of cancer-related death. With the recognizing the importance of long non-coding RNA (LncRNA) in development and cancer, it is urgently to identify new LncRNA and understand the mechanism to develop novel therapeutic strategies. Methods: Nine CRC cell lines, 52,146 and 285 cases of normal colorectal mucosa, adenoma and CRC samples were utilized. Northern blot, rapid amplification of cloned cDNA ends, RNA pulldown, Mass spectrum, RNA immunoprecipitation, CRISPR/Cas9, fluorescence Results: Lnc5q21.2 is identified to be a novel long intergenic non-coding RNA and its full length is 668 nt. Lnc5q21.2 is mainly located in cell nucleus and its expression is regulated by N Conclusions: Lnc5q21.2 is a novel lncRNA. Lnc5q21.2 promotes ATR pathway by activating Wnt signaling via interacting with HOXA10. Lnc5q21.2 sensitizes CRC cells to ATR inhibitor both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.